These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 8389666)

  • 1. Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors.
    Saltz L; Trochanowski B; Buckley M; Heffernan B; Niedzwiecki D; Tao Y; Kelsen D
    Cancer; 1993 Jul; 72(1):244-8. PubMed ID: 8389666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group.
    di Bartolomeo M; Bajetta E; Buzzoni R; Mariani L; Carnaghi C; Somma L; Zilembo N; di Leo A
    Cancer; 1996 Jan; 77(2):402-8. PubMed ID: 8625251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metastatic neuroendocrine hepatic tumors: resection improves survival.
    Musunuru S; Chen H; Rajpal S; Stephani N; McDermott JC; Holen K; Rikkers LF; Weber SM
    Arch Surg; 2006 Oct; 141(10):1000-4; discussion 1005. PubMed ID: 17043278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of sunitinib in patients with advanced neuroendocrine tumors.
    Kulke MH; Lenz HJ; Meropol NJ; Posey J; Ryan DP; Picus J; Bergsland E; Stuart K; Tye L; Huang X; Li JZ; Baum CM; Fuchs CS
    J Clin Oncol; 2008 Jul; 26(20):3403-10. PubMed ID: 18612155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours.
    Arnold R; Trautmann ME; Creutzfeldt W; Benning R; Benning M; Neuhaus C; Jürgensen R; Stein K; Schäfer H; Bruns C; Dennler HJ
    Gut; 1996 Mar; 38(3):430-8. PubMed ID: 8675099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms.
    Moertel CG; Kvols LK; O'Connell MJ; Rubin J
    Cancer; 1991 Jul; 68(2):227-32. PubMed ID: 1712661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence and morbidity of cholelithiasis in patients receiving chronic octreotide for metastatic carcinoid and malignant islet cell tumors.
    Trendle MC; Moertel CG; Kvols LK
    Cancer; 1997 Feb; 79(4):830-4. PubMed ID: 9024721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II trial of streptozotocin and adriamycin in advanced APUD tumors.
    Frame J; Kelsen D; Kemeny N; Cheng E; Niedzwiecki D; Heelan R; Lippermann R
    Am J Clin Oncol; 1988 Aug; 11(4):490-5. PubMed ID: 2841843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Phase II study of high-dose paclitaxel in patients with advanced neuroendocrine tumors.
    Ansell SM; Pitot HC; Burch PA; Kvols LK; Mahoney MR; Rubin J
    Cancer; 2001 Apr; 91(8):1543-8. PubMed ID: 11301403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatic artery chemoinfusion with chemoembolization for neuroendocrine cancer with progressive hepatic metastases despite octreotide therapy.
    Christante D; Pommier S; Givi B; Pommier R
    Surgery; 2008 Dec; 144(6):885-93; discussion 893-4. PubMed ID: 19040993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Somatostatin analog sandostatin and inhibition of tumor growth in patients with metastatic endocrine gastroenteropancreatic tumors.
    Arnold R; Neuhaus C; Benning R; Schwerk WB; Trautmann ME; Joseph K; Bruns C
    World J Surg; 1993; 17(4):511-9. PubMed ID: 8395752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues.
    Wolin EM; Jarzab B; Eriksson B; Walter T; Toumpanakis C; Morse MA; Tomassetti P; Weber MM; Fogelman DR; Ramage J; Poon D; Gadbaw B; Li J; Pasieka JL; Mahamat A; Swahn F; Newell-Price J; Mansoor W; Öberg K
    Drug Des Devel Ther; 2015; 9():5075-86. PubMed ID: 26366058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [New medical therapy of neuroendocrine gastrointestinal tumors].
    Eriksson B; Janson ET; Skogseid B; Oberg K
    Lakartidningen; 1990 Aug; 87(35):2668-72. PubMed ID: 2214974
    [No Abstract]   [Full Text] [Related]  

  • 14. Resistance of metastatic pancreatic endocrine tumours after long-term treatment with the somatostatin analogue octreotide (SMS 201-995).
    Wynick D; Anderson JV; Williams SJ; Bloom SR
    Clin Endocrinol (Oxf); 1989 Apr; 30(4):385-8. PubMed ID: 2557179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An important new treatment for carcinoid tumors and VIPomas.
    Oncology (Williston Park); 1988 Dec; 2(12):35-6. PubMed ID: 2856315
    [No Abstract]   [Full Text] [Related]  

  • 16. Combination therapy with octreotide and alpha-interferon: effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors.
    Frank M; Klose KJ; Wied M; Ishaque N; Schade-Brittinger C; Arnold R
    Am J Gastroenterol; 1999 May; 94(5):1381-7. PubMed ID: 10235222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Irinotecan plus cisplatin followed by octreotide long-acting release maintenance treatment in advanced gastroenteropancreatic neuroendocrine carcinoma: IPO-NEC study.
    Li J; Lu M; Lu Z; Li Z; Liu Y; Yang L; Li J; Zhang X; Zhou J; Wang X; Gong J; Gao J; Li Y; Shen L
    Oncotarget; 2017 Apr; 8(15):25669-25678. PubMed ID: 27788498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of type I gastric neuroendocrine tumors with somatostatin analogs.
    Khuroo MS; Khuroo MS; Khuroo NS
    J Gastroenterol Hepatol; 2010 Mar; 25(3):548-54. PubMed ID: 20074162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors.
    Kwekkeboom DJ; Teunissen JJ; Bakker WH; Kooij PP; de Herder WW; Feelders RA; van Eijck CH; Esser JP; Kam BL; Krenning EP
    J Clin Oncol; 2005 Apr; 23(12):2754-62. PubMed ID: 15837990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma.
    Shojamanesh H; Gibril F; Louie A; Ojeaburu JV; Bashir S; Abou-Saif A; Jensen RT
    Cancer; 2002 Jan; 94(2):331-43. PubMed ID: 11900219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.